- Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
- PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- 4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing
- PAVmed Provides Business Update and First Quarter 2024 Financial Results
- Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results
- Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
- Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
- PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
- Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
More ▼
Key statistics
On Friday, PAVmed Inc (PAVM:NAQ) closed at 0.708, 18.02% above the 52 week low of 0.5999 set on Jun 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.7201 |
---|---|
High | 0.7299 |
Low | 0.70 |
Bid | 0.70 |
Offer | 0.7609 |
Previous close | 0.708 |
Average volume | 47.65k |
---|---|
Shares outstanding | 9.43m |
Free float | 8.84m |
P/E (TTM) | -- |
Market cap | 6.68m USD |
EPS (TTM) | -9.08 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼